Maharashtra Bans Coldrif Syrup Linked to Child Deaths

Health

Updated on Oct - 06 - 2025, 01:34 PM

 

In a decisive move, the Maharashtra Food and Drug Administration (FDA) has imposed a statewide ban on Coldrif syrup (Batch No. SR-13) after it was linked to the deaths of at least 14 children in neighbouring states. The decision comes amid alarm over contamination by diethylene glycol (DEG), a toxic industrial chemical. 

The circular, signed by drug controller Dr. Gahane, directs that all sale, distribution, and consumption of the syrup be halted immediately. The FDA also urged hospitals, retailers and wholesalers to secure existing stock and inform local drug authorities. 

Coldrif is manufactured by Sresan Pharma in Kancheepuram, Tamil Nadu (manufacture May 2025, expiry April 2027). Investigations suggest that DEG might have been substituted possibly to cut cost posing grave risks including acute kidney failure. 

In parallel, the Nagpur division of FDA has also imposed restrictions on Anset syrup, a paediatric anti-emetic containing ondansetron, after safety concerns emerged. Families from Madhya Pradesh alleged that children died after consuming Coldrif; images of suspect syrups were shared, prompting tip offs and sampling in Nagpur. 

Testing is underway: over 20 cough syrup samples have reportedly been collected across the state. Though Coldrif hasn’t yet been detected in Nagpur, Anset samples were among those sent for testing. Wholesalers are under scrutiny too. The distributor of Anset has already paused supply pending results. 

Health experts warn that even trace amounts of DEG can cause organ damage, especially in children. The FDA in Maharashtra is coordinating with Tamil Nadu’s drug control authorities to trace the supply chain and prevent further fatalities. 

This ban and enforcement action underline the urgent need for vigilance in pharmaceutical regulation and prompt response when evidence implicates life-threatening contamination.